The term "dawn phenomenon" indicates a condition in which insulin requirements increase between 04.00 hours and 08.00 hours (or hyperglycaemia develops if the increased insulin requirements are not met) in the absence of declining insulin delivery or preceding hypoglycaemia [1] . The dawn phenomenon has been extensively studied in adults with Type 1 (insulindependent) [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] or Type 2 (non-insulin-dependent) diabetes [11] and in normal subjects [13] . However, there are no data available on its possible occurrence in Type I diabetic children and adolescents, in whom elevated pre-breakfast blood glucose (BG) are a common clinical observation. If, as shown by some authors [3, 4] , nocturnal growth hormone (GH) secretion is the main determinant of the dawn phenomenon, this latter should be particularly apparent in diabetic adolescents since these subjects present an important GH secretion both because of puberty and diabetes [14] [15] [16] [17] .
We therefore studied 8 children and adolescents with Type i diabetes, at various pubertal stages, in order to answer the two following questions: (1) Does the dawn phenomenon exist in these adolescents? (2) If yes, is the magnitude of dawn phenomenon related to nocturnal GH secretion, which would further support a major role of GH in its pathogenesis?
Subjects and methods

Patients
After approval of this study by our local Ethical Committee, informed consent was obtained from eight children and adolescents with Type I diabetes and from their parents. The patients (6 girls, 2 boys) were 8.2 to 19.2 years old (mean+ SEM = 14.1_ 1.2 years), had been diabetic from 2 to 6years (4.3+0.4years) and had a fasting Cpeptide below the limit of detectability of our assay (0.05 nmol/1). They were on a therapeutic regimen of 2 daily injections of a mixture of regular and intermediate acting insulins. Their glycosylated haemoglobin (HbA1, column chromatography) was 8.8+0.8 (normal range= 5-8.5%). All of them had normal growth and their weight was within 2 SD of the normal body weight for their height. They were of various Tanner pubertal stages (Table 1) , and therefore, presumably presented a wide range of GH nocturnal secretion.
Protocol
Intermediate acting and regular insulins were withdrawn 24 h and 7 h before admission (30 h and 13 h prior to the first blood sampiing). The subjects were admitted to the hospital at 16.00 hours on the study day. A 14-gauge catheter was inserted in a superficial forearm vein for insulin infusion. Regular insulin (Actrapid HM, Novo, Denmark, Copenhagen) was diluted in normal saline to a final concentration of 1 U/ml. The first few mls of solution were allowed to stand for 30 min in the plastic tubing and then discarded in order to saturate insulin absorption sites [18] . The same syringe and tubing were used throughout the entire study. Insulin was infused by means of a calibrated syringe pump (Robomedic 100, Gazuit Electronic, Domerat, France). A 20-gauge butterfly needle was inserted on the contralateral forearm for blood sampling and kept patent with normal saline (10 ml/h). Since the quality of sleep is a major determinant of nocturnal GH secretion [19] , it was essential to avoid any noise or movement near the patient and therefore blood sampling was performed by the investigator standing in an adjacent room through a 3 meter long tube, For each sample, the plastic tubing was first purged from saline and blood, a blood sample was withdrawn and finally the initially withdrawn blood and saline were slowly reinjected in order to minimise blood substraction. The patients were rendered euglycaemic between 16.30 hours and 19.00hours by an insulin infusion adjusted on frequent (5-15 min) BG determinations performed in duplicate with a reflectance meter (Dextrostix and Glucometer, Ames Company, Paris, France), which was carefully calibrated and double checked with an enzymatic blood glucose (BG) determination prior to each study.
At 19.00 hours, a standard meal was given (25% of the usual daily caloric intake, 50% carbohydrates, 35% fat, 15% protein) together with a bolus of insulin of approximately 1 U/10 g of carbohydrates. Patients were again rendered euglycaernic between 21.30 hours and 22.30 hours by adjusting the insulin infusion rate.
At 22.00 hours, a primed (approximately 4 mg/kg) constant (approximately 0.027 rag. kg -1. min -1) infusion of D-[6,6 2H2] glucose (CEA, Gif-sur-Yvette, France) was begun and continued throughout the study (n= 7). Between 22.00 hours and 01,00 hours, the insulin infusion rate needed to keep each subject euglycaemic (4.5-5.5 mmol/1) was carefully determined and then kept constant from 01.00 hours (at the latest) to 08.00 hours. No hypoglycaemia occurred in any patient during the study.
Blood was withdrawn at 40 min intervals from 01.00 hours to 08.00 hours for determination of BG, metabolites, [6, 6 2Hz ] glucose enrichment, free insulin and glucagon and at 20 min intervals from 23.00 hours to 08.00 hours for determination of plasma GH levels.
All the patients were sleeping by 23.00 hours and woke up between 07.15 and 08.00 hours.
Analytical procedure
Blood glucose, 3-hydroxybutyrate and plasma non-esterified fatty acids (NEFA) were assayed enzymatically as previously described [20] . Plasma D-[6,62H2] glucose enrichme.nts were determined by gas chromatography-mass spectrometry using the bisbutane boronyl acetyl derivative of glucose, as previously described [21, 22] . Plasma levels of C Peptide [23] , free insulin [23] , glucagon [24] and GH [25] were determined by radioimmunoassay. At GH plasma levels of 2.6, 6.4 and 20 ng/ml, the within and between assay coefficients of variation were, respectively 6,8%, 3,2%, 2% and 9.7%, 8.8%, 5.5%.
Statistical analysis
Rates of glucose production and utilisation were calculated by the non-steady state equations of de Bodo [26] using a pool fraction of 0.5. Integrated secretion of GH (area under the curve) was determined by the trapezoidal rule. Data are given as mean + SEM. Statistical analysis was done by two-way analysis of variance and paired Student's t-tests.
Results
The insulin infusion rate, determined in each patient between 22.00hours and 01.00hours, ranged from 0.18 to 0.44 mU-kg-l-min -1 (Table 1) Ol.OO 08.00 023'.00 01-00 03'.00 05'.00 ' 08~00 Time Fig. 1 . Overnight metabolic profiles of plasma free insulin, blood glucose, rates of glucose production (H) and utilisation (I, T) and plasma growth hormone levels in eight Type 1 (insulindependent) diabetic adolescents given a constant insulin infusion. Values are mean+SEM.*p<0.05; **p<0.01 compared with 01.00-03.00 hours values 01.00 hours (4.32 _+ 0.70 mmol/1) to 05.40 hours (5,24_+1.05mmol/1) and then rose to 7.14+1.15 mmol/l at 08.00hours (p<0.01vs 01.00-03.00hours values). The mean early morning (06.40-08.00 hours) BG value increased by 50% or more above the mean 01.00-03.00hours value in 5 out of 8patients (Table 1 ). There was an inverse relationship between this BG increase and the individual insulin infusion rate (r= -0.689, p< 0.05). Hepatic glucose production (n=7) was stable from 01.00hours (3.66+0.38mg kg --1 min -1) to 05.00hours (3.35mg.kg-t.min -1) and then increased moderately to 4.74mg.kg -t. min -~ at 08.00 hours (Fig. 1) . This rise was not significant (p> 0.05) because of different time courses from one patient to another. However, the rise of BG and hepatic glucose production (expressed as percentage of increase between the 06.40-08.00 hours values and the 01.00-03.00hours values) were positively correlated (r= 0.74, p<0.05). Glucose utilisation decreased slightly, but non-significantly from 01.00hours to 06.40 hours and then followed the rise of glucose production. Plasma non-esterified fatty acids (NEFA) levels did not change (01.00hours, 501+98~tmol/1; 08.00 hours, 556 • 118 ~tmol/1) while 3-hydroxybutyrate tended to increase although nonsignificantly (/)>0.05) (01.00 hours, 92• ~tmol/1; 08.00 hours, 217 + 55 ~tmol/l).
The mean values of plasma GH from 23.00 hours to 08.00 hours are depicted on the bottom panel of Figure 1 . The chronological patterns of nocturnal GH secretion were very different from one subject to another (Table 1 ). All the patients presented at least one peak above 20 ng/ml and 2 peaks above 7.5 ng/ml. Both peak GH values and areas under the curve appeared to be highest in subjects of Tanner pubertal stages III and IV.
There was a positive correlation between the insulin infusion rate delivered from 01.00 to 08.00 hours and the amount of GH (area under the curve) secreted either during the period of determination of this rate, i.e. from 23.00 to 01.00hours (r=0.775, p<0.05) or during the whole night, i.e. from 23.00 to 08.00 hours (r= 0.87, p< 0.01). On the contrary, no correlation was found between the nocturnal GH secretion (area under the curve) and the early morning rise of BG, whether this latter was expressed as the 08.00 hours BG value (r=-0.040, p>0.9) or as the absolute (mmol/l) or relative (%) increase of BG between dawn (06.40-08.00 hours) and the 01.00-03.00 hours period (respectively, r=-0A52, p>0.6 and r=-0.478, p> 0.2).
Discussion
Our data demonstrate that Type 1 diabetic adolescents receiving a constant, but individually predetermined overnight insulin infusion, present a moderate early morning BG rise. The insulin infusion rates were determined on the basis of bedside venous BG determination, using a reflectance meter, which is less accurate than a glucose analyser. However, extreme care was taken for these measurements (see Methods section) which were very close to the actual BG measured later on by an enzymatic method. The fact that the insulin infusion rates selected on this basis were able to maintain euglycaemia until 05.30 hours indicate that these rates were adequate for each patient.
Elevated pre-breakfast BG is a common feature in Type 1 diabetic patients and recognises three causes that can be additive: post-hypoglycaemic hyperglycaemia, underinsulinisation and dawn phenomenon.
(1) Hypoglycaemia did not occur in any of our patients which therefore excludes a rebound hyperglycaemia (Somogyi phenomenon). In keeping with this, the observed GH secretion was not the result of counterregulation and did correspond to a physiological GH profile. (2) Underinsulinisation is certainly relevant in clinical practice due to the waning of subcutaneously injected insulin. This was not the case in~ our subjects since BG, NEFA, ketone bodies and heJ patic glucose production remained constant until approximately 06.00 hours and since plasma free insulin levels were stable overnight. (3) A dawn phenomenon does occur in Type I diabetic adolescents according to our data, and is secondary to an increased hepatic glucose production, as previously shown [3, 4] , rather than to a decreased glucose utilisation. The rather elevated basal glucose production (3.66mg.kg-lmin -1) is related to the young age of our patients and our values are comparable to those found by Bier in normal adolescents (approximately 3.8 rag-kg -1. min -I in 40 kg adolescents) [21] . The overall amplitude of the dawn phenomenon was lower (mean 08.00 hours BG: 7.1 retool/l) than in previous studies [3] [4] [5] in Type 1 diabetic adults (mean 08.00 hours BG, 9.3-12.9 retool/ 1) using comparable protocols, i.e. a constant overnight insulin infusion.
The cause of the dawn phenomenon remains controversial. An increased metabolic clearance rate of insulin has been reported by many authors using a Biostator [3, 4, 8, 10, 27] . However, it was later shown [5, 28] that the rate of insulin delivered by the Biostatot, decreased slowly with time, resulting in a decreasing insulin concentration, and therefore in an artefactual increase of insulin metabolic clearance rate. As a matter of fact, when insulin was delivered with a syringe pump, the insulin clearance either increased very little [9, 29] or only in a few patients [27] , or did not change at all overnight [5, 12] which is further confirmed by our data.
Among the counterregulatory hormones, cortisol, glucagon and catecholamines have been successively ruled out [3, 7, 8] as causes for the dawn phenomenon. On the contrary, GH, which is able to induce insulin resistance [30, 31] and is mostly secreted during sleep could influence nocturnal glucose homeostasis. Two different questions should be considered. First, does GH play a role on the overnight insulin requirements; and second, does it play a role on the pre-breakfast BG rise, i.e. the dawn phenomenon?
The answer to the first question is that GH increases the overnight insulin requirements in Type 1 diabetic patients. The insulin needs of our patients were positively correlated with the overnight GH secretion. This is in keeping with the data of Amiel et al. [17] who demonstrated a negative relationship between insulin sensitivity and mean 24h GH secretion in diabetic adolescents. Similarly, Skor et al. have shown that nocturnal insulin requirements decreased by approximately 30% [10] when GH secretion was suppressed by somatostatin, this being true both from 01.00 to 03.00hours and from 06.00 hours to 8.00 hours. Finally, the high GH levels observed in our patients, comparable to those previously reported in Type I diabetic adolescents [14, 17] probably account for their elevated insulin requirements.
Second, a role of GH on the dawn phenomenon strictly speaking is far from clear. We were unable to find any significant correlation between GH secretion and the magnitude of the dawn phenomenon. In the study by Skor et al. [10] , the pre-breakfast increase in insulin requirement was not abolished by somatostatin. Mauras et al. [32] failed to detect a dawn phenomenon in normal subjects with markedly different patterns of GH secretion. These results are at variance with those of Campbell et al. [3, 4] who demonstrated a clear relationship between GH and the dawn phenomenon. A possible explanation for this discrepancy is that, in this latter study, all the patients received the same constant insulin infusion rate (0.15 mU.kg -1. rain-i). Given the individual variability of insulin requirements, it is possible that some subjects had been underinsulinised and that, in these latter, the hyperglycaemic effect of GH has been progressively unmasked during the night, resulting in a rise of BG correlated with GH secretion. Finally, a relative overnight underinsulinisation could also account for the difference of magnitude of the dawn phenomenon between data of Campbell et al. and ours. It is of interest to note that the dawn phenomenon begins early (03.30hours) when a standard insulin infusion is given [3, 4, 27] while, on the contrary, it begins only at 05.30 hours when the patients receive a variable insulin infusion [6, 11, 12] or an individually predetermined insulin infusion.
Other lines of evidence for a role of GH in the pathogenesis of the dawn phenomenon are also controversial. Its suppression by somatostatin was reported by Campbell [3] but not by Skor [10] . Finally, restoration of a dawn phenomenon by GH replacement (3) is difficult to interpret since normal GH plasma levels were obtained 30 rain after intravenous injections of GH. Given the very short half life of intravenous GH, the actual peaks of GH were likely to be much higher than those observed and could have resulted in pharmacological, rather than physiological, levels.
In summary, the present study indicates that (1) a dawn phenomenon of moderate amplitude exists in Type i diabetic adolescents, (2) overnight insulin requirements are influenced by GH nocturnal secretion, (3) if overnight insulinisation is adequate, GH does not appear to play a major role in the dawn phenomenon strictly speaking. If underinsulinisation occurs in the early morning, which is the case when insulin is injected subcutaneously prior to dinner, it could potentialize the dawn phenomenon. Our data do not support the proposed suppression of GH nocturnal surges by somatostatin analogs, a treatment that, in any case, would be unconceivable in growing children.
